<code id='152288D9C1'></code><style id='152288D9C1'></style>
    • <acronym id='152288D9C1'></acronym>
      <center id='152288D9C1'><center id='152288D9C1'><tfoot id='152288D9C1'></tfoot></center><abbr id='152288D9C1'><dir id='152288D9C1'><tfoot id='152288D9C1'></tfoot><noframes id='152288D9C1'>

    • <optgroup id='152288D9C1'><strike id='152288D9C1'><sup id='152288D9C1'></sup></strike><code id='152288D9C1'></code></optgroup>
        1. <b id='152288D9C1'><label id='152288D9C1'><select id='152288D9C1'><dt id='152288D9C1'><span id='152288D9C1'></span></dt></select></label></b><u id='152288D9C1'></u>
          <i id='152288D9C1'><strike id='152288D9C1'><tt id='152288D9C1'><pre id='152288D9C1'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:5847
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In